{"id":8793,"date":"2025-10-17T16:24:27","date_gmt":"2025-10-17T08:24:27","guid":{"rendered":"https:\/\/regask.com\/?p=8793"},"modified":"2025-10-17T16:24:27","modified_gmt":"2025-10-17T08:24:27","slug":"nuevo-programa-piloto-de-la-fda-que-podria-transformar-el-futuro-de-la-fabricacion-de-medicamentos-genericos-en-ee-uu","status":"publish","type":"post","link":"https:\/\/regask.com\/es\/new-fda-pilot-program-that-could-reshape-the-future-of-u-s-generic-drug-manufacturing\/","title":{"rendered":"Nuevo programa piloto de la FDA que podr\u00eda transformar el futuro de\u2026"},"content":{"rendered":"<p>The <a href=\"https:\/\/www.fda.gov\/\"><strong>U.S. Food and Drug Administration (FDA)<\/strong><\/a> has announced a <strong>pilot prioritization program<\/strong> for <strong>Abbreviated New Drug Applications (ANDAs)<\/strong> that supports <strong>domestic manufacturing and testing<\/strong>. The initiative, launched on <strong>October 3, 2025<\/strong>, aims to <strong>expedite review timelines<\/strong> for qualifying applications, <strong>reduce foreign dependency<\/strong>, and <strong>boost the resilience of the U.S. pharmaceutical supply chain<\/strong>.<\/p>\n<p>Under the pilot, generic drug manufacturers who conduct <strong>bioequivalence testing within the United States<\/strong>, produce <strong>finished dosage forms domestically<\/strong>, and source <strong>active pharmaceutical ingredients (APIs)<\/strong> exclusively from <strong>U.S.-based suppliers<\/strong> are eligible for <strong>priority review<\/strong>.<\/p>\n<p>This measure addresses both <strong>public health and national security risks<\/strong> by strengthening domestic R&amp;D capabilities and reducing the inspection of costs and delays associated with overseas manufacturing facilities.<\/p>\n<div class=\"row\"  id=\"row-639877221\">\n\n\t<div id=\"col-236019643\" class=\"col small-12 large-12\"  >\n\t\t\t\t<div class=\"col-inner\"  >\n\t\t\t\n\t\t\t\n<h3>Key Provisions and Eligibility<\/h3>\n\t<div id=\"gap-1630965601\" class=\"gap-element clearfix\" style=\"display:block; height:auto;\">\n\t\t\n<style>\n#gap-1630965601 {\n  padding-top: 15px;\n}\n<\/style>\n\t<\/div>\n\t\n<p>To qualify for <strong>priority review<\/strong>, ANDA applicants must fulfill <strong>all three<\/strong> of the following criteria:<\/p>\n<ol>\n<li>Conduct or obtain a waiver for <strong>bioequivalence testing<\/strong> in the U.S.<\/li>\n<li><strong>Manufacture finished dosage forms<\/strong><\/li>\n<li>Use <strong>API suppliers located in the U.S. <\/strong><a href=\"https:\/\/natlawreview.com\/article\/fda-launches-new-anda-prioritization-pilot-support-us-based-generic-manufacturing\"><strong><sup>[1]<\/sup><\/strong><\/a><\/li>\n<\/ol>\n<p>Applicants must reference <a href=\"https:\/\/www.fda.gov\/media\/89061\/download#:~:text=This%20MAPP%20describes%20how%20the%20review%20of%20original,Original%20ANDAs%2C%20Amendments%2C%20and%20Supplements%20%28January%2030%2C%202020%29.\"><strong>FDA\u2019s Manual of Policies and Procedures (MAPP) 5240.3<\/strong><\/a> when requesting prioritization under this pilot program. The program is open-ended, with <strong>no specified deadline<\/strong> for participation, allowing ongoing submissions under this framework.<\/p>\n\t\t<\/div>\n\t\t\t\t\n<style>\n#col-236019643 > .col-inner {\n  margin: 0px 0px -20px 0px;\n}\n<\/style>\n\t<\/div>\n\n\t\n\n\t<div id=\"col-1390634664\" class=\"col small-12 large-12\"  >\n\t\t\t\t<div class=\"col-inner\"  >\n\t\t\t\n\t\t\t\n<h3>Why It Matters<\/h3>\n\t<div id=\"gap-949241432\" class=\"gap-element clearfix\" style=\"display:block; height:auto;\">\n\t\t\n<style>\n#gap-949241432 {\n  padding-top: 15px;\n}\n<\/style>\n\t<\/div>\n\t\n<p>The pilot program represents a <strong>strategic shift toward onshoring critical pharmaceutical operations<\/strong>. With <strong>over 50% of pharmaceuticals distributed in the U.S. manufactured overseas<\/strong> and only <strong>9% of API manufacturers based domestically<\/strong>, <a href=\"https:\/\/www.fda.gov\/drugs\/news-events-human-drugs\/fda-public-meeting-onshoring-manufacturing-drugs-and-biological-products-09302025\"><sup>[2]<\/sup><\/a> this initiative supports <strong>supply chain security<\/strong>, <strong>faster market access for generics<\/strong>, and <strong>enhanced regulatory efficiency<\/strong>.<\/p>\n<p>By incentivizing local production and testing, the FDA aims to <strong>bolster public health infrastructure<\/strong>, <strong>stimulate domestic R&amp;D<\/strong>, and <strong>mitigate risks linked to international supply disruptions<\/strong>.<\/p>\n\t\t<\/div>\n\t\t\t\t\n<style>\n#col-1390634664 > .col-inner {\n  margin: 0px 0px -20px 0px;\n}\n<\/style>\n\t<\/div>\n\n\t\n\n\t<div id=\"col-768222808\" class=\"col small-12 large-12\"  >\n\t\t\t\t<div class=\"col-inner\"  >\n\t\t\t\n\t\t\t\n<h3>Who Should Take Note<\/h3>\n\t<div id=\"gap-611999261\" class=\"gap-element clearfix\" style=\"display:block; height:auto;\">\n\t\t\n<style>\n#gap-611999261 {\n  padding-top: 15px;\n}\n<\/style>\n\t<\/div>\n\t\n<p>This update is particularly relevant for <strong>regulatory affairs<\/strong>, <strong>quality assurance<\/strong>, and <strong>manufacturing operations teams<\/strong> within generic drug companies. Organizations preparing ANDA submissions should assess their <strong>manufacturing geography, testing practices, and supplier base<\/strong> to determine eligibility for the <strong>FDA\u2019s expedited review pathway<\/strong>.<\/p>\n\t\t<\/div>\n\t\t\t\t\n<style>\n#col-768222808 > .col-inner {\n  margin: 0px 0px -20px 0px;\n}\n<\/style>\n\t<\/div>\n\n\t\n\n\t<div id=\"col-1242061054\" class=\"col small-12 large-12\"  >\n\t\t\t\t<div class=\"col-inner\"  >\n\t\t\t\n\t\t\t\n<h3>Next Steps<\/h3>\n\t<div id=\"gap-1460436554\" class=\"gap-element clearfix\" style=\"display:block; height:auto;\">\n\t\t\n<style>\n#gap-1460436554 {\n  padding-top: 15px;\n}\n<\/style>\n\t<\/div>\n\t\n<p>Stakeholders are advised to:<\/p>\n<ul>\n<li>Review their manufacturing and testing workflows against the pilot\u2019s eligibility requirements.<\/li>\n<li>Reference <strong>MAPP 5240.3<\/strong> when submitting ANDAs to request prioritization.<\/li>\n<li>Maintain supporting documentation to demonstrate compliance with domestic sourcing and testing standards.<\/li>\n<\/ul>\n<p>For teams navigating regulatory submissions or preparing for shifting U.S. compliance frameworks, leveraging predictive and automated intelligence tools can ensure timely action and submission accuracy.<\/p>\n<p><a href=\"https:\/\/regask.com\/\"><strong>RegASK<\/strong><\/a> is a leading <strong>agentic AI regulatory intelligence and workflow orchestration platform<\/strong> that empowers global organizations in <strong>highly regulated sectors<\/strong>, including <strong>life sciences and consumer goods<\/strong>, to proactively navigate complex regulatory landscapes. By leveraging <strong>experts in the loop<\/strong>, RegASK delivers <strong>predictive actionable insights<\/strong>, <strong>end-to-end automation<\/strong>, and <strong>real-time compliance tracking<\/strong> across <strong>140+ countries <\/strong>streamlining submissions like ANDAs and accelerating market access.<br \/>\n<a href=\"https:\/\/regask.com\/product\/\"><strong>Learn more<\/strong><\/a><strong> or <\/strong><a href=\"https:\/\/regask.com\/book-a-demo\/\"><strong>book a demo now.<\/strong><\/a><\/p>\n\t\t<\/div>\n\t\t\t\t\n<style>\n#col-1242061054 > .col-inner {\n  margin: 0px 0px -20px 0px;\n}\n<\/style>\n\t<\/div>\n\n\t\n<\/div>\n<div class=\"row\"  id=\"row-1303688064\">\n\n\t<div id=\"col-937118331\" class=\"col small-12 large-12\"  >\n\t\t\t\t<div class=\"col-inner\"  >\n\t\t\t\n\t\t\t\n<div class=\"is-divider divider clearfix\" style=\"margin-top:2em;margin-bottom:2em;max-width:20%;height:1px;background-color:#a5acd9;\"><\/div>\n<h3>FAQs<\/h3>\n\t<div id=\"gap-1647715861\" class=\"gap-element clearfix\" style=\"display:block; height:auto;\">\n\t\t\n<style>\n#gap-1647715861 {\n  padding-top: 10px;\n}\n<\/style>\n\t<\/div>\n\t\n<h4>What is the FDA\u2019s new pilot program about?<\/h4>\n\t<div id=\"gap-316332963\" class=\"gap-element clearfix\" style=\"display:block; height:auto;\">\n\t\t\n<style>\n#gap-316332963 {\n  padding-top: 10px;\n}\n<\/style>\n\t<\/div>\n\t\n<p>The program prioritizes review of ANDAs for generic drugs manufactured and tested in the U.S., aiming to strengthen domestic production and reduce reliance on foreign suppliers.<\/p>\n\t\t<\/div>\n\t\t\t\t\n<style>\n#col-937118331 > .col-inner {\n  margin: 0px 0px -20px 0px;\n}\n<\/style>\n\t<\/div>\n\n\t\n\n\t<div id=\"col-1395328278\" class=\"col small-12 large-12\"  >\n\t\t\t\t<div class=\"col-inner\"  >\n\t\t\t\n\t\t\t\n<h4>What are the eligibility criteria for priority review?<\/h4>\n\t<div id=\"gap-2070063032\" class=\"gap-element clearfix\" style=\"display:block; height:auto;\">\n\t\t\n<style>\n#gap-2070063032 {\n  padding-top: 10px;\n}\n<\/style>\n\t<\/div>\n\t\n<p>ANDA applicants must conduct bioequivalence testing in the U.S., manufacture finished dosage forms domestically, and source APIs exclusively from U.S.-based suppliers.<\/p>\n\t\t<\/div>\n\t\t\t\t\n<style>\n#col-1395328278 > .col-inner {\n  margin: 0px 0px -20px 0px;\n}\n<\/style>\n\t<\/div>\n\n\t\n\n\t<div id=\"col-60858423\" class=\"col small-12 large-12\"  >\n\t\t\t\t<div class=\"col-inner\"  >\n\t\t\t\n\t\t\t\n<h4>Is there a submission deadline for this pilot program?<\/h4>\n\t<div id=\"gap-1219158977\" class=\"gap-element clearfix\" style=\"display:block; height:auto;\">\n\t\t\n<style>\n#gap-1219158977 {\n  padding-top: 10px;\n}\n<\/style>\n\t<\/div>\n\t\n<p>No, the FDA has not specified a deadline. Eligible ANDAs can be submitted on an ongoing basis under the pilot framework.<\/p>\n\t\t<\/div>\n\t\t\t\t\n<style>\n#col-60858423 > .col-inner {\n  margin: 0px 0px -20px 0px;\n}\n<\/style>\n\t<\/div>\n\n\t\n\n\t<div id=\"col-341566925\" class=\"col small-12 large-12\"  >\n\t\t\t\t<div class=\"col-inner\"  >\n\t\t\t\n\t\t\t\n<h4>How can RegASK support organizations with this FDA initiative?<\/h4>\n\t<div id=\"gap-720306637\" class=\"gap-element clearfix\" style=\"display:block; height:auto;\">\n\t\t\n<style>\n#gap-720306637 {\n  padding-top: 10px;\n}\n<\/style>\n\t<\/div>\n\t\n<p><a href=\"https:\/\/regask.com\/\">RegASK<\/a> Helps manufacturers and compliance teams monitor evolving FDA policies, automate documentation workflows, and align submission strategies with programs like the FDA\u2019s prioritization pilot to ensure faster, compliant market entry.<\/p>\n\t\t<\/div>\n\t\t\t\t\n<style>\n#col-341566925 > .col-inner {\n  margin: 0px 0px -20px 0px;\n}\n<\/style>\n\t<\/div>\n\n\t\n<\/div>\n<div class=\"row\"  id=\"row-2045876404\">\n\n\t<div id=\"col-805893235\" class=\"col small-12 large-12\"  >\n\t\t\t\t<div class=\"col-inner\"  >\n\t\t\t\n\t\t\t\n<div class=\"is-divider divider clearfix\" style=\"margin-top:2em;margin-bottom:2em;max-width:20%;height:1px;background-color:#a5acd9;\"><\/div>\n<h3>References<\/h3>\n\t<div id=\"gap-908376655\" class=\"gap-element clearfix\" style=\"display:block; height:auto;\">\n\t\t\n<style>\n#gap-908376655 {\n  padding-top: 10px;\n}\n<\/style>\n\t<\/div>\n\t\n<ol>\n<li><a href=\"https:\/\/natlawreview.com\/article\/fda-launches-new-anda-prioritization-pilot-support-us-based-generic-manufacturing\">Natlawreview &#8211; FDA Launches New ANDA Prioritization Pilot to Support U.S.-Based Generic Manufacturing<\/a><\/li>\n<li><a href=\"https:\/\/www.fda.gov\/drugs\/news-events-human-drugs\/fda-public-meeting-onshoring-manufacturing-drugs-and-biological-products-09302025\">gov &#8211; FDA Public Meeting: Onshoring Manufacturing of Drugs and Biological Products<\/a><\/li>\n<\/ol>\n\t\t<\/div>\n\t\t\t\t\n<style>\n#col-805893235 > .col-inner {\n  margin: 0px 0px -20px 0px;\n}\n<\/style>\n\t<\/div>\n\n\t\n<\/div>\n","protected":false},"excerpt":{"rendered":"<p>La Administraci\u00f3n de Alimentos y Medicamentos de EE. UU. (FDA) ha anunciado un programa piloto de priorizaci\u00f3n para las Solicitudes Abreviadas de Nuevos Medicamentos (ANDA) que apoya la fabricaci\u00f3n y las pruebas nacionales. La iniciativa, lanzada el 3 de octubre de 2025, busca agilizar los plazos de revisi\u00f3n de las solicitudes que cumplen los requisitos, reducir la dependencia extranjera y fortalecer la resiliencia de la cadena de suministro farmac\u00e9utica estadounidense. Bajo\u2026<\/p>","protected":false},"author":32,"featured_media":8794,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[527,33],"tags":[],"class_list":["post-8793","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-united-states-regulations","category-news"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.6 (Yoast SEO v27.6) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>New FDA Pilot Program to Transform Drug Manufacturing<\/title>\n<meta name=\"description\" content=\"Explore the New FDA Pilot Program that could reshape the future of U.S. generic drug manufacturing and enhance supply chains.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/regask.com\/es\/nuevo-programa-piloto-de-la-fda-que-podria-transformar-el-futuro-de-la-fabricacion-de-medicamentos-genericos-en-ee-uu\/\" \/>\n<meta property=\"og:locale\" content=\"es_ES\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"New FDA Pilot Program that Could Reshape the Future of U.S. Generic Drug Manufacturing\" \/>\n<meta property=\"og:description\" content=\"Explore the New FDA Pilot Program that could reshape the future of U.S. generic drug manufacturing and enhance supply chains.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/regask.com\/es\/nuevo-programa-piloto-de-la-fda-que-podria-transformar-el-futuro-de-la-fabricacion-de-medicamentos-genericos-en-ee-uu\/\" \/>\n<meta property=\"og:site_name\" content=\"RegASK\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/RegASKRegulatoryAffairs\/\" \/>\n<meta property=\"article:published_time\" content=\"2025-10-17T08:24:27+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/regask.com\/wp-content\/uploads\/2025\/10\/new-fda-pilot-program-could-reshape-future-us-generic-drug-manufacturing.png\" \/>\n\t<meta property=\"og:image:width\" content=\"800\" \/>\n\t<meta property=\"og:image:height\" content=\"600\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Hannah Nordin\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@ASKRegASK\" \/>\n<meta name=\"twitter:site\" content=\"@ASKRegASK\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Hannah Nordin\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutos\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/regask.com\\\/new-fda-pilot-program-that-could-reshape-the-future-of-u-s-generic-drug-manufacturing\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/regask.com\\\/new-fda-pilot-program-that-could-reshape-the-future-of-u-s-generic-drug-manufacturing\\\/\"},\"author\":{\"name\":\"Hannah Nordin\",\"@id\":\"https:\\\/\\\/regask.com\\\/#\\\/schema\\\/person\\\/3a8aaee2c7585284f97ec9e038e36b65\"},\"headline\":\"New FDA Pilot Program that Could Reshape the Future of &hellip;\",\"datePublished\":\"2025-10-17T08:24:27+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/regask.com\\\/new-fda-pilot-program-that-could-reshape-the-future-of-u-s-generic-drug-manufacturing\\\/\"},\"wordCount\":809,\"publisher\":{\"@id\":\"https:\\\/\\\/regask.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/regask.com\\\/new-fda-pilot-program-that-could-reshape-the-future-of-u-s-generic-drug-manufacturing\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/regask.com\\\/wp-content\\\/uploads\\\/2025\\\/10\\\/new-fda-pilot-program-could-reshape-future-us-generic-drug-manufacturing.png\",\"articleSection\":[\"United States\",\"Regulatory News\"],\"inLanguage\":\"es\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/regask.com\\\/new-fda-pilot-program-that-could-reshape-the-future-of-u-s-generic-drug-manufacturing\\\/\",\"url\":\"https:\\\/\\\/regask.com\\\/new-fda-pilot-program-that-could-reshape-the-future-of-u-s-generic-drug-manufacturing\\\/\",\"name\":\"New FDA Pilot Program to Transform Drug Manufacturing\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/regask.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/regask.com\\\/new-fda-pilot-program-that-could-reshape-the-future-of-u-s-generic-drug-manufacturing\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/regask.com\\\/new-fda-pilot-program-that-could-reshape-the-future-of-u-s-generic-drug-manufacturing\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/regask.com\\\/wp-content\\\/uploads\\\/2025\\\/10\\\/new-fda-pilot-program-could-reshape-future-us-generic-drug-manufacturing.png\",\"datePublished\":\"2025-10-17T08:24:27+00:00\",\"description\":\"Explore the New FDA Pilot Program that could reshape the future of U.S. generic drug manufacturing and enhance supply chains.\",\"inLanguage\":\"es\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/regask.com\\\/new-fda-pilot-program-that-could-reshape-the-future-of-u-s-generic-drug-manufacturing\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"es\",\"@id\":\"https:\\\/\\\/regask.com\\\/new-fda-pilot-program-that-could-reshape-the-future-of-u-s-generic-drug-manufacturing\\\/#primaryimage\",\"url\":\"https:\\\/\\\/regask.com\\\/wp-content\\\/uploads\\\/2025\\\/10\\\/new-fda-pilot-program-could-reshape-future-us-generic-drug-manufacturing.png\",\"contentUrl\":\"https:\\\/\\\/regask.com\\\/wp-content\\\/uploads\\\/2025\\\/10\\\/new-fda-pilot-program-could-reshape-future-us-generic-drug-manufacturing.png\",\"width\":800,\"height\":600,\"caption\":\"New Fda Pilot Program Could Reshape Future Us Generic Drug Manufacturing\"},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/regask.com\\\/#website\",\"url\":\"https:\\\/\\\/regask.com\\\/\",\"name\":\"RegASK\",\"description\":\"The Regulatory AI Operating System for High-Performing Teams\",\"publisher\":{\"@id\":\"https:\\\/\\\/regask.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/regask.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"es\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/regask.com\\\/#\\\/schema\\\/person\\\/3a8aaee2c7585284f97ec9e038e36b65\",\"name\":\"Hannah Nordin\",\"sameAs\":[\"https:\\\/\\\/regask.com\"]}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Nuevo programa piloto de la FDA para transformar la fabricaci\u00f3n de medicamentos","description":"Explore el nuevo programa piloto de la FDA que podr\u00eda transformar el futuro de la fabricaci\u00f3n de medicamentos gen\u00e9ricos en EE. UU. y mejorar las cadenas de suministro.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/regask.com\/es\/nuevo-programa-piloto-de-la-fda-que-podria-transformar-el-futuro-de-la-fabricacion-de-medicamentos-genericos-en-ee-uu\/","og_locale":"es_ES","og_type":"article","og_title":"New FDA Pilot Program that Could Reshape the Future of U.S. Generic Drug Manufacturing","og_description":"Explore the New FDA Pilot Program that could reshape the future of U.S. generic drug manufacturing and enhance supply chains.","og_url":"https:\/\/regask.com\/es\/nuevo-programa-piloto-de-la-fda-que-podria-transformar-el-futuro-de-la-fabricacion-de-medicamentos-genericos-en-ee-uu\/","og_site_name":"RegASK","article_publisher":"https:\/\/www.facebook.com\/RegASKRegulatoryAffairs\/","article_published_time":"2025-10-17T08:24:27+00:00","og_image":[{"width":800,"height":600,"url":"https:\/\/regask.com\/wp-content\/uploads\/2025\/10\/new-fda-pilot-program-could-reshape-future-us-generic-drug-manufacturing.png","type":"image\/png"}],"author":"Hannah Nordin","twitter_card":"summary_large_image","twitter_creator":"@ASKRegASK","twitter_site":"@ASKRegASK","twitter_misc":{"Written by":"Hannah Nordin","Est. reading time":"4 minutos"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/regask.com\/new-fda-pilot-program-that-could-reshape-the-future-of-u-s-generic-drug-manufacturing\/#article","isPartOf":{"@id":"https:\/\/regask.com\/new-fda-pilot-program-that-could-reshape-the-future-of-u-s-generic-drug-manufacturing\/"},"author":{"name":"Hannah Nordin","@id":"https:\/\/regask.com\/#\/schema\/person\/3a8aaee2c7585284f97ec9e038e36b65"},"headline":"New FDA Pilot Program that Could Reshape the Future of &hellip;","datePublished":"2025-10-17T08:24:27+00:00","mainEntityOfPage":{"@id":"https:\/\/regask.com\/new-fda-pilot-program-that-could-reshape-the-future-of-u-s-generic-drug-manufacturing\/"},"wordCount":809,"publisher":{"@id":"https:\/\/regask.com\/#organization"},"image":{"@id":"https:\/\/regask.com\/new-fda-pilot-program-that-could-reshape-the-future-of-u-s-generic-drug-manufacturing\/#primaryimage"},"thumbnailUrl":"https:\/\/regask.com\/wp-content\/uploads\/2025\/10\/new-fda-pilot-program-could-reshape-future-us-generic-drug-manufacturing.png","articleSection":["United States","Regulatory News"],"inLanguage":"es"},{"@type":"WebPage","@id":"https:\/\/regask.com\/new-fda-pilot-program-that-could-reshape-the-future-of-u-s-generic-drug-manufacturing\/","url":"https:\/\/regask.com\/new-fda-pilot-program-that-could-reshape-the-future-of-u-s-generic-drug-manufacturing\/","name":"Nuevo programa piloto de la FDA para transformar la fabricaci\u00f3n de medicamentos","isPartOf":{"@id":"https:\/\/regask.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/regask.com\/new-fda-pilot-program-that-could-reshape-the-future-of-u-s-generic-drug-manufacturing\/#primaryimage"},"image":{"@id":"https:\/\/regask.com\/new-fda-pilot-program-that-could-reshape-the-future-of-u-s-generic-drug-manufacturing\/#primaryimage"},"thumbnailUrl":"https:\/\/regask.com\/wp-content\/uploads\/2025\/10\/new-fda-pilot-program-could-reshape-future-us-generic-drug-manufacturing.png","datePublished":"2025-10-17T08:24:27+00:00","description":"Explore el nuevo programa piloto de la FDA que podr\u00eda transformar el futuro de la fabricaci\u00f3n de medicamentos gen\u00e9ricos en EE. UU. y mejorar las cadenas de suministro.","inLanguage":"es","potentialAction":[{"@type":"ReadAction","target":["https:\/\/regask.com\/new-fda-pilot-program-that-could-reshape-the-future-of-u-s-generic-drug-manufacturing\/"]}]},{"@type":"ImageObject","inLanguage":"es","@id":"https:\/\/regask.com\/new-fda-pilot-program-that-could-reshape-the-future-of-u-s-generic-drug-manufacturing\/#primaryimage","url":"https:\/\/regask.com\/wp-content\/uploads\/2025\/10\/new-fda-pilot-program-could-reshape-future-us-generic-drug-manufacturing.png","contentUrl":"https:\/\/regask.com\/wp-content\/uploads\/2025\/10\/new-fda-pilot-program-could-reshape-future-us-generic-drug-manufacturing.png","width":800,"height":600,"caption":"New Fda Pilot Program Could Reshape Future Us Generic Drug Manufacturing"},{"@type":"WebSite","@id":"https:\/\/regask.com\/#website","url":"https:\/\/regask.com\/","name":"RegASK","description":"El sistema operativo de IA regulatoria para equipos de alto rendimiento","publisher":{"@id":"https:\/\/regask.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/regask.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"es"},{"@type":"Person","@id":"https:\/\/regask.com\/#\/schema\/person\/3a8aaee2c7585284f97ec9e038e36b65","name":"Hannah Nordin","sameAs":["https:\/\/regask.com"]}]}},"_links":{"self":[{"href":"https:\/\/regask.com\/es\/wp-json\/wp\/v2\/posts\/8793","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/regask.com\/es\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/regask.com\/es\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/regask.com\/es\/wp-json\/wp\/v2\/users\/32"}],"replies":[{"embeddable":true,"href":"https:\/\/regask.com\/es\/wp-json\/wp\/v2\/comments?post=8793"}],"version-history":[{"count":0,"href":"https:\/\/regask.com\/es\/wp-json\/wp\/v2\/posts\/8793\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/regask.com\/es\/wp-json\/wp\/v2\/media\/8794"}],"wp:attachment":[{"href":"https:\/\/regask.com\/es\/wp-json\/wp\/v2\/media?parent=8793"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/regask.com\/es\/wp-json\/wp\/v2\/categories?post=8793"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/regask.com\/es\/wp-json\/wp\/v2\/tags?post=8793"}],"curies":[{"name":"Gracias","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}